NIKKEI 225
38,482.11 +379.67 (+1.00%) HANG SENG
17,915.55 -20.57 (-0.11%) CRUDE OIL
81.46 +1.13 (+1.41%) GOLD FUTURES
2,344.80 +15.80 (+0.68%) DOW
38,834.86 +56.76 (+0.15%) Bitcoin GBP
50,734.96 -1,557.23 (-2.98%)
REGN Jan 2025 790.000 put
| Previous close | 7.50 |
| Open | 7.70 |
| Bid | 2.20 |
| Ask | 9.20 |
| Strike | 790.00 |
| Expiry date | 2025-01-17 |
| Day's range | 7.50 - 7.70 |
| Contract range | N/A |
| Volume | |
| Open interest | 40 |
ZacksRegeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
GlobeNewswireUpdated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
Simply Wall St.Investors in Regeneron Pharmaceuticals (NASDAQ:REGN) have seen stellar returns of 220% over the past five years
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
